At a glance
ClinicalIndex Comparison RecordN/ACompleted· 11,060 enrolled
Drug / intervention
fluticasone propionate/salmeterol xinafoate combinationdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)
In Brief
An observational study evaluating fluticasone propionate/salmeterol xinafoate combination for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 11,060 participants.
Detailed Summary
The specific aim of this study is to describe 1 year Advair dispensing rates for patients with COPD, and to measure the association between Advair adherence and healthcare utilization (e.g. emergency room visits and inpatient admissions, etc.). To compare the risk of a COPD exacerbation (moderate or severe) during a 3-month follow-up period between patients thqat are adherent versus those that are not.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
Primary CompletionMay 2010
First PostedJun 2011
TodayJul 2026
First PostedJun 27, 2011
Enrollment StartAug 1, 2009
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.0 years ago
Interventions
fluticasone propionate/salmeterol xinafoate combinationdrug
fluticasone propionate/salmeterol xinafoate combination